Enregistrement - Lobbyistes salariés d'entreprises

Objets

• Affaires autochtones
• Commerce international
• Développement économique
• Développement international
• Développement régional
• Impôts et finances
• Industrie
• Marchés publics
• Propriété intellectuelle
• Questions constitutionnelles
• Recherche et développement
• Relations internationales
• Santé
• Sciences et technologies
• Vie privée et Accès à l'information

Détails sur l'objet

Politique ou Programme

• Canada's Access to Medicines Regime (CAMR) with regard to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
• Canada's Food and Consumer Safety Action Plan with regard to ensuring that patient safety is a priority in a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.
• Cost Recovery Initiative, ensuring a framework where user fees adequately fund a safe and efficient review process.
• National Pharmaceutical Strategy (NPS) with regard to ensuring development or implementation of any policies or programs include consultations with all affected stakeholders and focus on bettering access to medicines for Canadians.
• Patented Medicines Price Review Board (PMPRB) with regard to ensuring that PMPRB Guidelines, Policies and Procedures reflect PMPRB mandate to ensure that prices charged for patented medicines in Canada are not excessive and that potential changes consider impact to the pharmaceutical industry.
• Public policy issues related to Health Canada's review of NCE
• Science and Technology (S&T) Strategy with regard to ensuring that the implementation of that strategy encourages a public policy environment that attracts business investment in innovation and enhances the ability of Canadian industry to compete internationally.
• Scientific Research and Experimental Development (SR&ED) Tax Incentive Program with regard to expansion of eligible expenditures to recognize the impact on innovation and the research and development (R&D) investment by the pharmaceutical industry in Canada.
• The Canada-European Union Comprehensive Economic and Trade Agreement (CETA) negotiations with respect to biopharmaceuticals and intellectual property right protection.
• Through Innovation, Science & Industry discuss opportunities to enhance the Canadian life sciences sector including, biomanufacturing, partnerships, R&D investments.

Politique ou Programme, Règlement

• Blueprint for Renewal with regard to ensuring a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.
• Representation with Ministry of Health and Public Service Procurement Canada to achieve emergency approval, procurement and utilization of the AZD1222 vaccine (Covishield) and long-acting antibody (LAAB) combination AZD7442 to fight the Covid-19 pandemic.

Règlement

• Patented Medicine Prices Review Board (PMPRB) with regard to ensuring guidelines also provide incentives for innovation through research and development in addition to PMPRB mandate of protection from excessive prices.
• Patented Medicines (Notice Of Compliance) Regulations with regard to ensuring that Canada's intellectual property (IP) laws and regulations are internationally competitive and continue to provide a stable and predictable business environment to encourage continued pharmaceutical investment in Canada.

Techniques de communication

• Communication écrite
• Communication orale

Institutions gouvernementales

• Affaires mondiales Canada (AMC)
• Agence canadienne de développement économique du Nord (CanNor)
• Agence de la santé publique du Canada (ASPC)
• Agence de promotion économique du Canada atlantique (APECA)
• Agence du revenu du Canada (ARC)
• Agence fédérale de développement économique pour le Sud de l'Ontario (FedDev)
• Agriculture et Agroalimentaire Canada (AAC)
• Anciens Combattants Canada (ACC)
• Bureau de la concurrence Canada (BUCO)
• Bureau du Conseil privé (BCP)
• Cabinet du Premier ministre (CPM)
• Centre de recherches pour le développement international (CRDI)
• Chambre des communes
• Conseil d'examen du prix des médicaments brevetés (CEPMB)
• Conseil de recherches en sciences naturelles et en génie (CRSNG)
• Conseil national de recherches (CNRC)
• Défense nationale (MDN)
• Développement économique Canada pour les régions du Québec
• Diversification de l'économie de l'Ouest Canada (DEO)
• Finances Canada (FIN)
• Fondation canadienne pour l'innovation
• Gendarmerie royale du Canada (GRC)
• Innovation, Sciences et Développement économique Canada (ISDE)
• Instituts de recherche en santé du Canada (IRSC)
• Santé Canada (SC)
• Secrétariat du Conseil du Trésor du Canada (SCT)
• Sénat du Canada
• Services publics et Approvisionnement Canada (SPAC)
• Tribunal canadien du commerce extérieur (TCCE)

Adresse :
1004 Middlegate Road, Suite 5000
Mississauga, ON  L4Y 1M4
Canada

Numéro de téléphone : 800-565-5877

Renseignements sur la société mère